Solid BiosciencesNASDAQ: SLDB

Solid Biosciences (NASDAQ: SLDB) recently released their first quarter 2024 financial results, reporting an earnings per share of -64 cents.

Solid Biosciences is concentrating on advancing gene therapy for neuromuscular and cardiac disorders, with their primary focus being on a drug therapy for Duchenne muscular dystrophy (DMD) that is scheduled for testing in the second quarter of 2024. The company has recently received added funding from a private investment in public equity (PIPE), which has enhanced its risk-reward balance.

Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.

British billionaire Joe Lewis, who owns the Tottenham Hotspur football club, has pleaded guilty to insider trading charges in New York, after prosecutors had charged him with sharing secret stock tips with his pilots, girlfriends and assistants for years.

Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs market is expected to reach $27.4 billion by 2030. Solid Biosciences might be able to overcome gene therapy competitors in the DMD space with its own proprietary capsid of AAV-SLB101, which may end up having better transgene expression.

The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.

Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.